Investor Relations

Company Overview

We aspire to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer.

Our lead investigational drug candidate is relugolix, a small molecule, GnRH receptor antagonist. We have three clinical programs for relugolix which consisted of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 & 2), two in women with endometriosis-associated pain (SPIRIT 1 & 2), and one in men with advanced prostate cancer (HERO). We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, as a potential treatment for women undergoing assisted reproduction, such as in vitro fertilization (IVF).

Over time, we intend to expand our development pipeline to include other potential treatments for women's health and prostate cancer.

Copyright West LLC. Share price minimum 15 minutes delayed. Market cap from previous market close.

Press Releases
November 23, 2020
Myovant Sciences to Present at Upcoming December Investor Conferences
November 17, 2020
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
November 12, 2020
Myovant Sciences Announces Corporate Updates and Financial Results for Second Quarter Fiscal Year 2020
Events

SEC Filings

Filing date Description Form View

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA